| Greenwood Transitional Rehabilitation Unit | |
| 1530 Parkway, Greenwood, South Carolina 29646 | |
| (864) 330-9070 | |
| Name | Greenwood Transitional Rehabilitation Unit |
|---|---|
| Location | 1530 Parkway, Greenwood, South Carolina |
| Certified By | Medicare |
| No. of Certified Beds | 12 |
| Occupancy Rate | 67.5% |
| Medicare ID (CCN) | 425388 |
| Legal Business Name | Legal Business Name Not Available |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1457573875 |
| Organization Name | GREENWOOD REGIONAL REHABILITATION HOSPITAL LLC |
| Doing Business As | GREENWOOD TRANSITIONAL REHABILITATION UNIT |
| Address | 1530 Parkway, Greenwood, SC 29646 |
| Phone Number | 505-856-5300 |
News Archive
A recent study published in the journal Nature Medicine, led by researchers Todd Allen, PhD, a professor of Medicine at Harvard Medical School and group leader at the Ragon Institute of MGH, MIT and Harvard, and Jim Riley, PhD, a professor of Microbiology in the Perelman School of Medicine at the University of Pennsylvania, describes a new Dual CAR T cell immunotherapy that can help fight HIV infection.
Researchers have discovered a gene that modifies the severity of lung disease in people with the lethal genetic condition, cystic fibrosis, pointing to possible new targets for treatment, according to a new study in Nature.
Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, announces the addition of over 1,700 new chiral HPLC/SFC applications to its online resource, including more than 400 new SFC (supercritical fluid chromatography) methods. Phenomenex's extensive chiral application database is unique in the industry, particularly with the addition of the SFC methods, which were developed in collaboration with the Department of Analytical Chemistry and Pharmaceutical Technology, Vrije Universiteit Brussel, Brussels, Belgium.
Cepheid today announced the international availability of an update to Xpert Carba-R, with the addition of two newly emerging carbapenemase genes, OXA-181 and OXA-232. The on-demand, molecular test also detects and differentiates among the five most prevalent mechanisms of carbapenem resistance, namely KPC, NDM, VIM, IMP-1 and OXA-48.
A selection of health policy stories from Minnesota, Colorado, New York, Delaware, Georgia, Oregon, Connecticut, Pennsylvania, Arizona, Massachusetts and California.
› Verified 5 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
A recent study published in the journal Nature Medicine, led by researchers Todd Allen, PhD, a professor of Medicine at Harvard Medical School and group leader at the Ragon Institute of MGH, MIT and Harvard, and Jim Riley, PhD, a professor of Microbiology in the Perelman School of Medicine at the University of Pennsylvania, describes a new Dual CAR T cell immunotherapy that can help fight HIV infection.
Researchers have discovered a gene that modifies the severity of lung disease in people with the lethal genetic condition, cystic fibrosis, pointing to possible new targets for treatment, according to a new study in Nature.
Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, announces the addition of over 1,700 new chiral HPLC/SFC applications to its online resource, including more than 400 new SFC (supercritical fluid chromatography) methods. Phenomenex's extensive chiral application database is unique in the industry, particularly with the addition of the SFC methods, which were developed in collaboration with the Department of Analytical Chemistry and Pharmaceutical Technology, Vrije Universiteit Brussel, Brussels, Belgium.
Cepheid today announced the international availability of an update to Xpert Carba-R, with the addition of two newly emerging carbapenemase genes, OXA-181 and OXA-232. The on-demand, molecular test also detects and differentiates among the five most prevalent mechanisms of carbapenem resistance, namely KPC, NDM, VIM, IMP-1 and OXA-48.
A selection of health policy stories from Minnesota, Colorado, New York, Delaware, Georgia, Oregon, Connecticut, Pennsylvania, Arizona, Massachusetts and California.
› Verified 5 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|